Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 14, 2024 (2 years ago)

Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension, 1%, 0.5%, 0.075%, 5mL, Quantity: 20mL, Rx Only, Compounded by: Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ NDC 71384-310-05

Affected NDC 71384-0310-05

Compare with the code on your package — it is the most precise check available.

Drug: Moxifloxacin Category: Eye Drops & Ophthalmic

Recalling firm
Imprimis NJOF, LLC
NDC code
71384-310-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0548-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Moxifloxacin recalls

See all

Other recalls by Imprimis NJOF, LLC

All 2024 recalls